NCT04154488View on ClinicalTrials.gov

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 16, 2021

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions
Neutropenia
Interventions
DRUG

Mavorixafor

Mavorixafor capsules will be administered per dose and schedule specified in the arm.

Trial Locations (7)

19104

Children's Hospital of Philadelphia, Philadelphia

33701

USF Health Department of Pediatrics, St. Petersburg

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospital and Clinics, Iowa City

63110

Washington University School of Medicine, St Louis

75235

University of Texas, Southwestern, Dallas

98195

University of Washington, Seattle

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY

NCT04154488 - A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | Biotech Hunter | Biotech Hunter